Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

173.79 -0.21 (-0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
48 49 Next >
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Biogen Inc. Q2 Earnings And Revenues Surpass Estimates
Biogen Inc. came out with quarterly earnings of $5.25 per share. 
Via Talk Markets
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050. 
Via Benzinga
Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen's Q2 Highlights
Via Benzinga
Recap: Biogen Q2 Earnings
  Biogen (NASDAQ:BIIB) reported its Q2 earnings results on Wednesday, July 20, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biogen Stock Falls Despite Beat-And-Raise Q2 Report
Biogen stock fell early Wednesday after the biotech company reported adjusted profit of $5.25 per share on sales $2.59 billion in Q2. 
Via Investor's Business Daily
Analyst Ratings for Biogen
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter: 
Via Benzinga
Investors Turn Their Attention To The Earning Season
US stock indices rose on Tuesday as investors temporarily put aside recession fears and dived into the reporting season. 
Via Talk Markets
Earnings Scheduled For July 20, 2022
Companies Reporting Before The Bell • Wipro (NYSE:WIT) is projected to report quarterly earnings at $0.08 per share on revenue of $2.80 billion. 
Via Benzinga
Netflix Earnings NFLX In Motion - What Levels are in Play and also for Tesla TSLA Tomorrow?
Netflix reported earnings right after the bell Tuesday and shares surged right on the announcement - but will they hold going into Wednesday morning? 
Via Talk Markets
Apple Upstages Goldman Sachs On Monday, Bringing Rally To A Screeching Halt
(Tuesday Market Open) A big slide in the U.S. dollar appears to be pushing stocks higher Tuesday as a slew of earnings arrived before the opening bell. 
Via Benzinga
Biogen's Earnings Outlook
Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Wednesday, 2022-07-20. Here's what investors need to know before the announcement. Analysts estimate that Biogen will report... 
Via Benzinga
Tesla, Twitter, Goldman Among Headline Earnings Of Unfolding Week: Here Are The Key Earnings Ahead
The June quarter reporting season is entering its second week, with the focus gradually shifting from banks to technology companies. 
Via Benzinga
Bank Of America And Goldman Sachs Split On Earnings Reports, Possibly Putting Bank Rally In Jeopardy
(Monday Market Open) Investors around the globe appear to be starting the new trading week with a positive attitude as Asian and European markets traded higher overnight helping to boost U.S. equity... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Another Way To Understand Market Momentum
(Friday Market Open) U.S. equity futures moved higher early Friday as investors digested better-than-expected June retail sales data and China’s worst GDP numbers since the start of the pandemic. Later... 
Via Benzinga
Hot Inflation And Earnings Misses Weigh On Equity Futures
(Thursday Market Open) The equity markets may take another hit today as JPMorgan Chase (NYSE: JPM) and Morgan Stanley (NYSE: MS) kicked off a new earnings season with a couple of misses as eq 
Via Benzinga
Looking Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has fallen 4.95% since its last report. The company recently reported that it has 2.52 million shares sold short, which is 1.73% of... 
Via Benzinga
The Fed's Pickle: Whether to Raise Rates to Fight Inflation While Increasing Recession Chances
(Wednesday Market Open) The June Consumer Price Index (CPI) came in much hotter than expected, and equity index futures tumbled before the open.  
Via Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.87% on an annualized basis producing an average annual return of 10.15%. Currently, Biogen has a market capitalization of... 
Via Benzinga
Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why
The company's IPF treatment is proving itself where others didn't. 
Via Investor's Business Daily
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
3 Biotech Stocks to Sell Now
These biotech stocks remain vulnerable to more downside. Their charts remain broken and resistance looms ominously overhead. 
Via InvestorPlace
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors. 
Via Benzinga
Peering Into Biogen's Recent Short Interest
Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of... 
Via Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of... 
Via Benzinga
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.